1. Home
  2. ZLAB vs RARE Comparison

ZLAB vs RARE Comparison

Compare ZLAB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • RARE
  • Stock Information
  • Founded
  • ZLAB 2013
  • RARE 2010
  • Country
  • ZLAB China
  • RARE United States
  • Employees
  • ZLAB N/A
  • RARE N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • RARE Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZLAB Health Care
  • RARE Health Care
  • Exchange
  • ZLAB Nasdaq
  • RARE Nasdaq
  • Market Cap
  • ZLAB 3.6B
  • RARE 3.5B
  • IPO Year
  • ZLAB 2017
  • RARE 2014
  • Fundamental
  • Price
  • ZLAB $33.57
  • RARE $26.23
  • Analyst Decision
  • ZLAB Buy
  • RARE Strong Buy
  • Analyst Count
  • ZLAB 5
  • RARE 15
  • Target Price
  • ZLAB $54.28
  • RARE $87.40
  • AVG Volume (30 Days)
  • ZLAB 718.8K
  • RARE 2.6M
  • Earning Date
  • ZLAB 08-07-2025
  • RARE 07-31-2025
  • Dividend Yield
  • ZLAB N/A
  • RARE N/A
  • EPS Growth
  • ZLAB N/A
  • RARE N/A
  • EPS
  • ZLAB N/A
  • RARE N/A
  • Revenue
  • ZLAB $418,326,000.00
  • RARE $590,689,000.00
  • Revenue This Year
  • ZLAB $44.07
  • RARE $18.94
  • Revenue Next Year
  • ZLAB $49.13
  • RARE $28.61
  • P/E Ratio
  • ZLAB N/A
  • RARE N/A
  • Revenue Growth
  • ZLAB 43.72
  • RARE 33.46
  • 52 Week Low
  • ZLAB $16.01
  • RARE $26.01
  • 52 Week High
  • ZLAB $44.34
  • RARE $60.37
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 44.39
  • RARE 27.80
  • Support Level
  • ZLAB $32.31
  • RARE $26.85
  • Resistance Level
  • ZLAB $36.53
  • RARE $42.37
  • Average True Range (ATR)
  • ZLAB 1.11
  • RARE 1.72
  • MACD
  • ZLAB -0.20
  • RARE -1.21
  • Stochastic Oscillator
  • ZLAB 27.12
  • RARE 2.80

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: